跳至主要内容
临床试验/NL-OMON46974
NL-OMON46974已完成不适用

The VENUS (Verifying the Effectiveness of the NUsurface® System) Clinical Study - VENUS study

Active Implants LLC0 个研究点目标入组 14 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Inclusion Criteria: In the opinion of the investigator, if ALL of the following 8 conditions are applicable for the index knee, then the patient is included if he/she: ;1. Had > 6 months ago a medial partial meniscectomy as confirmed by patient history and MRI
  • 2. Has a KOOS Pain of * 75 (100 being the highest attainable and no pain)
  • 3. Is between age 30 and 75 years (inclusive) at the time of study treatment
  • 4. Has neutral alignment ± 5º of the mechanical axis, i.e., the angle formed by a line drawn from the center of the femoral head to the medial tibial spine and a line drawn from the medial tibial spine
  • to the center of the ankle joint
  • 5. Has * 2 mm intact medial meniscal rim capable of being fitted with a NUsurface® device AND is also recommended for the baseline non-surgical (and, if likely to receive benefit, any injection)
  • therapies to be administered in the study.
  • 6. Is willing to be entered into either arm of the study: implanted with the NUsurface device OR
  • treated with the recommended control arm therapies.
  • 7. Is able to do the study required follow up visits, questionnaires, X-rays, and MRI*s
  • 8. Is able and willing to understand and sign the study Informed Consent Form
  • 9. Is able to read and understand the national language of the country in which the relevant clinical site is located

排除标准

  • Exclusion Criteria: If ANY of the following 35 conditions are applicable, then the patient is excluded if he/she:;1) Has a symptomatic knee because of a tear that could be addressed by a repeat partial
  • meniscectomy leaving > 4 mm of medial meniscus rim
  • 2) Has evidence of a Outerbridge Grade IV cartilage loss on the medial tibial plateau or femoral
  • condyle that potentially could contact a NUsurface implant (e.g., a focal lesion > 0.5 cm correlating to a circular defect of > 8 mm in diameter)
  • 3) Has complete disruption of the posterior root attachment of the meniscus
  • 4) Has lateral compartment pain and Grade III or Grade IV Outerbridge cartilage score in the lateral
  • compartment
  • 5) Has a varus or valgus knee deformity > 5º requiring a tibial or femoral osteotomy
  • 6) Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior
  • cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament
  • (LCL) and/or medial collateral ligament (MCL)
  • 7) Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment
  • 8) Has patellar compartment pain and Grade III or Grade IV Outerbridge cartilage score in the
  • patellar compartment.
  • 9) Compared to a normal knee, has obvious radiological evidence of medial femoral squaring,
  • anatomical variance in the medial tibial plateau, or irregularly shaped cartilage surface
  • 10) Had an ACL reconstruction performed < 9 months prior to study treatment
  • 11) Has a BMI > 32.5 at the time of study treatment
  • 12) Decides to receive (if eligible and an option) allograft medial meniscus transplantation
  • 13) Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or
  • ceramic, not including the NUsurface® Meniscus Implant
  • 14) Has a knee flexion contracture > 10º
  • 15) Has flexion < 90º
  • 16) Had a previous medial femoral condyle surgery (not including microfracture) or High Tibial
  • Osteotomy (HTO)
  • 17) Has insufficiency fractures or avascular necrosis of the medial compartment
  • 18) Has an active infection or tumor (local or systemic)
  • 19) Has any type of knee joint inflammatory disease including Sjogren*s syndrome
  • 20) Has neuropathic knee osteoarthropathy, also known as Charcot joint
  • 21) Has any medical condition that does not allow possible arthroscopy of the knee
  • 22) Has neurological deficit (sensory, motor, or reflex)
  • 23) Is currently involved in another investigation of the lower extremity
  • 24) Anticipates having another lower extremity surgery during the study period
  • 25) Is contraindicated for hyaluronic acid injections (i.e., patients with known hypersensitivity [allergy] to hyaluronan [sodium hyaluoronate] preparations); patients having knee joint infections or skin diseases or infections in the site of possible injections
  • 26) Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura)
  • 27) Has received any corticosteroid knee injections * 3 months prior to study treatment
  • 28) Has chondrocalcinosis
  • 29) Is on immunostimulating or immunosuppressing agents
  • 30) Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or KOOS
  • (e.g. have a leg length discrepancy > 2.5 cm [1 inch], causing a noticeable limp)
  • 31) Is a female who is

研究者

相似试验

The VENUS (Verifying the Effectiveness of the... | 临床试验